{"url_path":"/sec/rvrc/8-k/2026-06-01/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1839140/0001213900-26-063235-index.html","accession_number":"0001213900-26-063235","cik":"0001839140","ticker":"RVRC","issuer_name":"Revium Rx.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1839140/0001213900-26-063235-index.html","primary_entity_key":"0001839140","primary_entity_name":"Revium Rx."},"word_count":323,"has_tables":true,"body_markdown":"**Item 5.02 Departure of Directors or Certain\nOfficers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.**\n\n \n\nResignation of Mr. Arie\nGordashnikov from his position as Chief Financial Officer\n\n \n\nOn May 27, 2026, Mr. Arie\nGordashnikov resigned from his position as Chief Financial Officer of Revium Rx. (“we,” “us,” “our,”\n“Revium” or the “company”) and of its subsidiaries, effective immediately. Mr. Gordashnikov’s resignation\ndid not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.\n\n \n\nAppointment of Mr. Igor\nBluvstein as Chief Financial Officer\n\n \n\nOn May 27, 2026, our Board\nof Directors appointed Mr. Igor Bluvstein to serve as the Chief Financial Officer of the Company and of its subsidiaries, effective immediately.\n\n \n\nPrior to his appointment as\nChief Financial Officer, from 2024 through 2025, Mr. Bluvstein served as Chief Financial Officer of Argent BioPharma Ltd. (ASX: RGT; LSE:\nRGT; OTCQB: RGTLF) and from 2022 through 2024 as Chief Financial Officer of G Medical Innovations Holdings Ltd. (NASDAQ: GMVD). Mr. Bluvstein,\n44, has over seventeen (17) years of experience in financial leadership across the pharmaceutical, digital health, biotechnology, e-commerce,\nand petrochemical industries. Earlier in his career, from 2020 through 2022 he served as Chief Financial & Operations Officer of MDD\nGroup and from 2016 through 2020 as Regional Chief Financial Officer at Frutarom Industries Ltd. (acquired by International Flavors &\nFragrances Inc. (NYSE: IFF)). Mr. Bluvstein holds a Bachelor of Arts in Accounting and Economics from the Open University of Israel. He\nis a Certified Public Accountant (CPA).\n\n \n\nIn connection with his appointment,\nMr. Bluvstein will receive a monthly retainer of NIS17,000 plus VAT.\n\n  \n\n1\n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**REVIUM Rx.**\n\n \n \n \n\nJune 1, 2026\nBy:\n/s/ Amir Avraham\n\n \n \nName:\nAmir Avraham\n\n \n \nTitle:\nChief Executive Officer\n\n \n\n \n\n2"}